Why One Healthcare Fund Increased Its Kodiak Sciences Stake Amid an Eye-Popping Rally

1 hour ago 3

Jonathan Ponciano, The Motley Fool

Sun, May 17, 2026 astatine 3:17 PM CDT 4 min read

Boxer Capital Management accrued its involvement successful Kodiak Sciences (NASDAQ:KOD) during the archetypal quarter, adding 225,000 shares successful a transaction estimated astatine $5.81 cardinal based connected quarterly mean pricing, according to a May 15, 2026, SEC filing.

What happened

According to a SEC filing dated May 15, 2026, Boxer Capital Management accrued its presumption successful Kodiak Sciences by 225,000 shares implicit the archetypal quarter. The estimated transaction worth was $5.81 million, based connected the mean closing terms for the quarter. The fund’s involvement successful Kodiak Sciences stood astatine 1,361,000 shares, with a quarter-end marketplace worth of $51.88 million. The nett presumption worth alteration for the 4th was $20.12 million, which includes some trading enactment and terms movement.

What other to cognize

Boxer Capital Management was a nett purchaser of Kodiak Sciences, with the post-trade involvement representing 6.81% of its 13F reportable AUM.
Top 5 holdings aft the filing:
- NASDAQ:TNGX: $227.53 cardinal (29.9% of AUM)
- NASDAQ:KOD: $51.88 cardinal (6.8% of AUM)
- NASDAQ:RVMD: $48.62 cardinal (6.4% of AUM)
- NASDAQ:KYMR: $27.41 cardinal (3.6% of AUM)
- NASDAQ:CELC: $25.68 cardinal (3.4% of AUM)
As of May 14, 2026, Kodiak Sciences shares were priced astatine $38.70, up a staggering 1,000% implicit the past twelvemonth and vastly outperforming the S&P 500’s astir 25% summation successful the aforesaid period.

Company Overview

Metric

Value

Price (as of marketplace adjacent 2026-05-14)	$38.70
Market capitalization	$2 billion
Net income (TTM)	($230.66 million)

Company Snapshot

Kodiak Sciences develops and commercializes therapeutics for retinal diseases, with pb merchandise campaigner KSI-301 successful late-stage objective trials for bedewed age-related macular degeneration, diabetic macular edema, and different retinal conditions.
The steadfast operates a clinical-stage biopharmaceutical concern exemplary processing proprietary cause candidates; arsenic of the latest reporting period, Kodiak Sciences Inc. reported nary revenue.
It targets ophthalmologists, retina specialists, and healthcare providers treating patients with retinal diseases, focusing connected the planetary ophthalmology market.

Kodiak Sciences Inc. is simply a clinical-stage biotechnology institution specializing successful the improvement of innovative therapeutics for retinal diseases. The institution leverages its proprietary antibody biopolymer conjugate level to beforehand a pipeline of differentiated cause candidates, aiming to code important unmet needs successful ophthalmology. With a absorption connected late-stage objective improvement and a robust pipeline, Kodiak Sciences seeks to found a competitory borderline done caller therapies targeting some prevalent and underserved retinal conditions.

Read Entire Article